Related Experiment Video
Updated: Oct 10, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Interventional magnetic-resonance-guided cryotherapy combined with microsurgery for recurrent glioblastoma: An
H Cebula1, J Garnon2, J Todeschi1
1Department of Neurosurgery, University Hospital of Strasbourg, Strasbourg, France.
Background:
Glioblastoma invariably recurs after primary Stupp tumor therapy and portends a poor prognosis. Cryoablation is a well-established treatment strategy for extra-cranial tumors. The safety and efficacy of interventional MR-guided cryoablation (iMRgC) has not been explored in recurrent glioblastoma.
Methods:
A retrospective analysis of data collected over a period of 24 months was performed. The inclusion criteria were: (I) recurrent glioblastoma despite Stupp protocol; (II) MRI followed by histological confirmation of recurrent glioblastoma; (III) location allowing iMRgC followed by microsurgical resection; and (IV) patient's consent. The primary objective was to assess feasibility in terms of complications. The secondary objective was to analyze progression-free survival (PFS), post-iMRgC survival and overall survival (OS).
Results:
The study included 6 patients, with a mean age of 67±7.6 years [range, 54-70 years]. No major complications were observed. Median PFS was 7.5 months [IQR 3.75-9.75] and 6-month PFS was 50%. Median post-iMRgC survival was 9 months [IQR 7.5-15.25] and 6-month post-iMRgC survival was 80%. Median OS was 22.5 months [IQR 21.75-30].
Conclusion:
iMRgC for recurrent glioblastoma demonstrated a good safety profile, with no major complications. Our data suggest improved PFS and OS.
Trial Registration Number:
No. IRB00011687 retrospectively registred on July 7th 2021.
Insights
Interventional MR-guided cryoablation (iMRgC) shows promise for recurrent glioblastoma, offering a good safety profile. This innovative treatment may improve progression-free and overall survival in glioblastoma patients.
Area of Science:
- Neurosurgery
- Oncology
- Interventional Radiology
Background:
- Glioblastoma recurrence after standard therapy presents a significant clinical challenge with poor prognosis.
- Cryoablation is an established technique for extra-cranial tumors, but its application in recurrent glioblastoma is unexplored.
- Interventional MR-guided cryoablation (iMRgC) offers a novel approach for localized tumor treatment.
Purpose of the Study:
- To evaluate the feasibility and safety of iMRgC in patients with recurrent glioblastoma.
- To assess the impact of iMRgC on progression-free survival (PFS) and overall survival (OS).
- To analyze post-procedure survival outcomes following iMRgC and microsurgical resection.
Main Methods:
- Retrospective analysis of 6 patients with recurrent glioblastoma over 24 months.
- Inclusion criteria: recurrent glioblastoma post-Stupp protocol, confirmed diagnosis, suitable tumor location for iMRgC and resection, and patient consent.
- Primary endpoint: assessment of complications; Secondary endpoints: PFS, post-iMRgC survival, and OS.
Main Results:
- No major complications were observed in the study cohort (n=6).
- Median PFS was 7.5 months, with a 6-month PFS rate of 50%.
- Median post-iMRgC survival was 9 months (80% at 6 months), and median OS was 22.5 months.
Conclusions:
- iMRgC demonstrates a favorable safety profile for recurrent glioblastoma, with no major complications reported.
- Preliminary data suggest that iMRgC may lead to improved PFS and OS in patients with recurrent glioblastoma.
- iMRgC represents a potentially valuable addition to the treatment armamentarium for recurrent glioblastoma.
